Recent press releases from two new partners of NextGenNK highlight important advances in natural killer (NK) cell-based immunotherapies, spanning both clinical development and translational research.
Coeptis Therapeutics has secured worldwide rights to the next-generation GEAR™ Cell Therapy Platform and formed a new subsidiary, GEAR Therapeutics, to advance GEAR-modified NK cells toward first-in-human cancer studies. The platform aims to enhance antibody-based cancer therapies while reducing NK cell fratricide, potentially improving clinical benefit.
Meanwhile, Karolinska Institutet and Cellply have launched a collaboration using Cellply's VivaCyte platform to support translational NK cell research. The initiative focuses on single-cell NK characterization and biomarker discovery to accelerate the development of more effective NK-based therapies.
